•y•y•yThe BDI-II is able to dist<strong>in</strong>guish among vary<strong>in</strong>g levels <strong>of</strong> depressiveseverity (Steer, Brown, Beck, & S<strong>and</strong>erson, 2001)Several studies have demonstrated high <strong>in</strong>ternal consistency with<strong>in</strong> <strong>the</strong>BDI-II, <strong>and</strong> <strong>the</strong> average coefficient alpha was .91 (range = .89–.93; Wiebe& Penly, 2005)The BDI-II has been validated with a range <strong>of</strong> diverse cultural populations(Gro<strong>the</strong> et al., 2005; Penley, Wiebe, & Nwosu, 2003), <strong>and</strong> has beentranslated <strong>in</strong>to several languages<strong>Co</strong>ncerns•y Research <strong>in</strong>dicates that <strong>the</strong> BDI should not be used as a sole <strong>in</strong>dicator<strong>of</strong> depression, but ra<strong>the</strong>r <strong>in</strong> conjunction with o<strong>the</strong>r <strong>in</strong>struments (Weiss& Mir<strong>in</strong>, 1989; Willenbr<strong>in</strong>g, 1986). Like o<strong>the</strong>r screen<strong>in</strong>g <strong>in</strong>struments, <strong>the</strong>BDI-II is not a diagnostic tool, <strong>and</strong> elevated scores do not necessarilyreflect a major depressive disorder, but <strong>the</strong> existence <strong>of</strong> depressed moodover <strong>the</strong> past two weeks•y Because <strong>the</strong> BDI measures subjective feel<strong>in</strong>gs <strong>of</strong> depression, it is difficultto discrim<strong>in</strong>ate normal <strong>in</strong>dividuals who are experienc<strong>in</strong>g sadness from<strong>in</strong>dividuals who are cl<strong>in</strong>ically depressed (Hesselbrock, Hesselbrock, Tennen,Meyer, & Workman, 1983)•y The BDI-II does not differentiate among vary<strong>in</strong>g types <strong>of</strong> mood disorders(e.g., major depressive disorder <strong>and</strong> dysthymia; Richter, Werner, Heerle<strong>in</strong>,Kraus, & Sauer, 1998)•y The BDI-II is significantly correlated with gender (women score higher),<strong>and</strong> <strong>the</strong> correlation decreases with age <strong>and</strong> across racial/ethnic groups.Although Beck, Brown, <strong>and</strong> Steer (1989) acknowledge gender differences<strong>in</strong> <strong>the</strong> frequency <strong>and</strong> severity <strong>of</strong> depressive symptoms, only a s<strong>in</strong>gle set <strong>of</strong>criterion-referenced <strong>in</strong>terpretive guidel<strong>in</strong>es is <strong>of</strong>feredAvailability <strong>and</strong> <strong>Co</strong>stThe BDI-II can be purchased from Harcourt <strong>Assessment</strong> at http://harcourtassessment.com/haiweb/cultures/en-us/productdetail.htm?pid=015-8018-370. The cost is $79 for one manual <strong>and</strong> 25 record forms.Brief Jail Mental Health Screen (BJMHS)The BJMHS was developed through fund<strong>in</strong>g by <strong>the</strong> National Institute <strong>of</strong><strong>Justice</strong> <strong>and</strong> was validated us<strong>in</strong>g a sample <strong>of</strong> over 10,000 deta<strong>in</strong>ees <strong>in</strong> four jails.The BJMHS was derived from <strong>the</strong> Referral Decision Scale (RDS), which wasdesigned to aid correctional staff <strong>in</strong> <strong>the</strong> identification <strong>of</strong> <strong>in</strong>dividuals who havesevere mental disorders (Steadman, Scott, Osher, Agnese, & Robb<strong>in</strong>s, 2005). Indevelop<strong>in</strong>g <strong>the</strong> screen, <strong>the</strong> total number <strong>of</strong> RDS items was reduced, several itemswere rephrased, <strong>and</strong> <strong>the</strong> assessed time span for symptom occurrence was changedfrom lifetime to <strong>the</strong> past six months. The BJMHS consists <strong>of</strong> six items thatexam<strong>in</strong>e <strong>the</strong> occurrence <strong>of</strong> mental health symptoms <strong>and</strong> two items that review63
prior hospitalization for mental health problems <strong>and</strong> current use <strong>of</strong> psychotropicmedication.Positive Features•y The Brief Jail Mental Health Screen is quick to adm<strong>in</strong>ister (i.e., takesapproximately five m<strong>in</strong>utes)•y The <strong>in</strong>strument was validated us<strong>in</strong>g <strong>the</strong> SCID, which is generallyacknowledged as <strong>the</strong> highest st<strong>and</strong>ard <strong>in</strong> assess<strong>in</strong>g mental disorders•y The <strong>in</strong>strument has been tested <strong>in</strong> forensic populations <strong>and</strong> is readilyadaptable for use <strong>in</strong> correctional screen<strong>in</strong>g processes•y Little formal tra<strong>in</strong><strong>in</strong>g is required to adm<strong>in</strong>ister <strong>and</strong> score <strong>the</strong> <strong>in</strong>strument<strong>Co</strong>ncerns•y The screen is more effective for men than women <strong>and</strong> has an “unacceptablyhigh” rate <strong>of</strong> false-negatives for female deta<strong>in</strong>ees (Steadman et al., 2005)•y The <strong>in</strong>strument does not screen for <strong>the</strong> entire spectrum <strong>of</strong> mentaldisorders, <strong>and</strong> is focused on <strong>the</strong> most severe disordersAvailability <strong>and</strong> <strong>Co</strong>stThe BJMHS <strong>in</strong>strument may be obta<strong>in</strong>ed without charge by contact<strong>in</strong>g <strong>the</strong>CMHS National GAINS Center at www.ga<strong>in</strong>scenter.samsha.govBrief Symptom Inventory (BSI)The BSI (Derogatis & Melisaratos, 1983) is a brief, self-report screen for mentalhealth symptoms. The 53-item <strong>in</strong>strument was developed from its longerpredecessor, <strong>the</strong> Symptom Checklist 90–Revised (SCL90-R), <strong>and</strong> is especiallyuseful <strong>in</strong> monitor<strong>in</strong>g treatment outcomes <strong>and</strong> provid<strong>in</strong>g a summary <strong>of</strong> symptomsat a specific po<strong>in</strong>t <strong>in</strong> time. The BSI <strong>in</strong>cludes n<strong>in</strong>e Primary Symptom Dimensions(scales) <strong>in</strong>clud<strong>in</strong>g Somatization, Obsessive-<strong>Co</strong>mpulsive, Interpersonal Sensitivity,Depression, Anxiety, Hostility, Phobias, Paranoid Ideation, <strong>and</strong> Psychoticism.In addition, <strong>the</strong>re are three Global Indices: Global Severity Index (GSI),measur<strong>in</strong>g overall psychological distress; Positive Symptom Distress Index(PSDI), measur<strong>in</strong>g <strong>the</strong> <strong>in</strong>tensity <strong>of</strong> symptoms; <strong>and</strong> <strong>the</strong> Positive Symptom Total(PST), measur<strong>in</strong>g <strong>the</strong> number <strong>of</strong> self-reported symptoms. There is also a brieferversion <strong>of</strong> <strong>the</strong> BSI (<strong>the</strong> Brief Symptom Inventory-18), which can be completed<strong>in</strong> approximately four m<strong>in</strong>utes. The BSI-18 has three Symptom Dimensions(Somatization, Depression, <strong>and</strong> Anxiety) <strong>and</strong> one Global Index, <strong>the</strong> GSI. A Pr<strong>of</strong>ileReport is also provided, which presents raw <strong>and</strong> normalized T scores for each <strong>of</strong><strong>the</strong> Primary <strong>and</strong> Global Scales. An Interpretive Report (not available with <strong>the</strong>BSI-18) provides a narrative summary <strong>of</strong> symptoms <strong>and</strong> scale scores. A ProgressReport is available to monitor an <strong>in</strong>dividual’s progress over time.64
- Page 1:
Screening and Assessmentof Co-Occur
- Page 5 and 6:
Screening Instruments for Co-Occurr
- Page 12 and 13:
daunting task, and often requires t
- Page 14 and 15:
Importance of Screening and Assessm
- Page 16 and 17:
•y•y•y•y•y•y•y•y•
- Page 18 and 19:
Developing a Comprehensive Screenin
- Page 20 and 21:
•y•y•y•y•y•y•y•y•
- Page 22 and 23: These areas of cognitive and behavi
- Page 24 and 25: •y•y•y•y•y•y•y•yAlc
- Page 26 and 27: frequency of drug testing may be ta
- Page 28 and 29: offer expanded tests that also incl
- Page 30 and 31: self-disclosure of mental health or
- Page 32 and 33: should be determined by the severit
- Page 34 and 35: Special Clinical Issues in Screenin
- Page 36: suicide screening is important for
- Page 39 and 40: Maintaininga staff ofdiverse ethnic
- Page 41 and 42: The MHSF-III and the GAIN-SS were f
- Page 43 and 44: Key Information to Include in Asses
- Page 45 and 46: •y•y`` Vocational and education
- Page 47 and 48: approximately two hours. Either the
- Page 49 and 50: Texas Christian University Drug Scr
- Page 51 and 52: & Cirimele, 2006). Hair testing can
- Page 53 and 54: Appendix B: Screening Instruments f
- Page 55 and 56: Suicide Probability Scale (SPS)The
- Page 57 and 58: Positive Features•y•y•yThe TS
- Page 59 and 60: Appendix D: Screening Instruments f
- Page 61 and 62: Positive Features•y•y•y•yTh
- Page 63 and 64: Positive Features•y•y•y•y
- Page 65 and 66: Appendix F: Screening Instruments T
- Page 67 and 68: Availability and CostThe CAMH-CDS i
- Page 69 and 70: and one Axis II disorder (antisocia
- Page 71: Appendix G: Screening Instruments f
- Page 75 and 76: •yThe instrument has been used wi
- Page 77 and 78: •yThe instrument has not been use
- Page 79 and 80: Appendix H: Screening Instruments f
- Page 81 and 82: Positive Features•y•y•y•y
- Page 83 and 84: have you felt you ought to Cut down
- Page 85 and 86: Concerns•y•y•yThe DALI was de
- Page 87 and 88: •y•y•y•y•y•y•ywith sc
- Page 89 and 90: Concerns80•y•y•y•y•y•y
- Page 91 and 92: Concerns•y The validity of the SS
- Page 93 and 94: Appendix I: Recommended Instruments
- Page 95 and 96: Concerns•y•y•y•yReliabiliti
- Page 97 and 98: •y•y•y•yScales and profile
- Page 99 and 100: •y•yand non-interpretable resul
- Page 101 and 102: Appendix L: Assessment Instruments
- Page 103 and 104: Philadelphia, PA 19106, (215) 399-0
- Page 105 and 106: treatment setting. Treatment progra
- Page 107 and 108: Concerns•y•y•yThe CIDI is qui
- Page 109 and 110: •y•y•yThe PDSQ has been used
- Page 111 and 112: Both a Research Version and a Clini
- Page 113 and 114: 104
- Page 115 and 116: Bastiaens, L., Riccardi, K., & Sakh
- Page 117 and 118: Carey, K. B., Carey, M. P., & Chand
- Page 119 and 120: Demmel, R., Beck, B., Richter, D.,
- Page 121 and 122: Gray, B. T. (2001). A factor analyt
- Page 123 and 124:
Kessler, R. C., Wittchen, H. U., Ab
- Page 125 and 126:
McLellan, A. T., Cacciola, J. S., &
- Page 127 and 128:
Nochajski, T. H., & Stasiewicz, P.
- Page 129 and 130:
Rollnick, H., Heather, N., Gold, R.
- Page 131 and 132:
Teitelbaum L. M., & Mullen, B. (200
- Page 133:
Zimmerman, M., & Sheeran, T. (2003)